A5077844105- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Healthcare Systems and Public Health
- Multiple Sclerosis Research Studies
- Medical Imaging and Pathology Studies
- Global Health Care Issues
- Biosimilars and Bioanalytical Methods
- Systemic Lupus Erythematosus Research
- Endometriosis Research and Treatment
- Pharmaceutical industry and healthcare
- Radiopharmaceutical Chemistry and Applications
- Pediatric Urology and Nephrology Studies
- Pharmaceutical Practices and Patient Outcomes
- Antibiotic Use and Resistance
- Healthcare Policy and Management
- Venous Thromboembolism Diagnosis and Management
- Multiple and Secondary Primary Cancers
- Atrial Fibrillation Management and Outcomes
- Hepatitis C virus research
- Vacuum and Plasma Arcs
- Prostate Cancer Treatment and Research
- Advanced Causal Inference Techniques
Slovak Medical University
2012-2021
Comenius University Bratislava
2011-2014
Managed entry agreements (MEAs) are a set of instruments to facilitate access new medicines. This study surveyed the implementation MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available.We conducted survey on CEE between January March 2017.Sixteen countries participated this study. Across five with available data number different MEA implemented, most common implemented were confidential discounts (n = 495, 73%), followed by paybacks 92, 14%),...
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, not necessarily linked to gain and the implications sustainability of their healthcare systems.Areas covered: Narrative discussion principally payers advisers potential approaches pricing medicines.Expert opinion: A number discussed including minimum effectiveness levels managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing,...
There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there safety and/or budget concerns. Dabigatran, a oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst effective treatments needed, issues elderly dabigatran due variable drug concentrations, no known antidote dependence on renal elimination. Published studies have shown be cost-effective but...
Introduction There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need review value among lower- middle-income countries (LMICs) which greatest prevalence both infectious noninfectious diseases issues affordability.Areas covered Review potential advantages, disadvantages,...
Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability.The enhanced use low cost generics could help.Aims: Consequently, there is a need to comprehensively document current future arrangements regarding the pricing generic across Europe, whether these indication specific, as well how this translates into actual prices provide direction.Methodology: Mixed method approach qualitative research...
Introduction: In January 2018 the European Commission published a Proposal for Regulation on Health Technology Assessment (HTA): 'Proposal health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication efficiency. There were however concerns its legal basis, establishment single managing authority, preservation national jurisdiction over HTA...
Introduction:The manufacturer of pregabalin has a second use patent covering prescribing for neuropathic pain -its principal indication.The threatened legal action in the UK if generic rather than Lyrica is prescribed this indication.No problems exist practitioners who prescribe epilepsy or generalized anxiety disorder.This serious implications health authorities.In Germany, however, historically generics can be legally any approved indication once one loses its patent.Aim: To establish...
Introduction: Although there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity patient access to biopharmaceuticals only based on their availability national list reimbursed medicines. Hidden barriers may facilitate financial sustainability pharmaceuticals less affluent EU countries; however, they have rarely been documented scientific publications. Our objective was explore these for tumor necrosis factor (TNF) alpha inhibitors rheumatoid...
Introduction/Objectives: Health authorities are facing increasing challenges to the sustainability of their healthcare systems because growing expenditures on medicines, including new, high-priced oncology and changes in disease prevalence ageing populations. Medicine prices European countries greatly affected by ability negotiate reasonable prices. Concerns have been expressed that patented medicines do not fall sufficiently after introduction lower-cost generic medicines. The objective...
To estimate the cost effectiveness of dienogest versus GnRH analogue (GnRH-a) for treatment endometriosis-associated chronic pelvic pain in Slovakia 5 years time horizon. A cost-utility Markov model based on results randomized controlled trial (AU19) was adapted to a Slovakian setting. The AU19 trial, which compared and GnRH-a (leuprolide) over 6 month period, showed no statistically significant differences response rates. annual relapse rate derived from 52-weeks extension study, while...
The aim of this study was to investigate the socio-economic impact chronic autoimmune diseases, mainly rheumatoid arthritis (RA) and work disabilities, among patients in Slovakia. Patients were prospectively recruited National Institute for Rheumatic Diseases Slovakia during year 2014 data from on disease their life collected by consulting physicians through a specifically designed questionnaire. sample (100 respondents) predominantly female (82%) with diagnosis RA (86%). As many as 66%...